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Abstract
Introduction The immunosuppressive therapy with everolimus (ERL) after heart transplantation is characterized by a narrow 
therapeutic window and a substantial variability in dose requirement. Factors explaining this variability are largely unknown.
Objectives Our aim was to evaluate factors affecting ERL metabolism and to identify novel metabolites associated with the 
individual ERL dose requirement to elucidate mechanisms underlying ERL dose response variability.
Method We used liquid chromatography coupled with mass spectrometry for quantification of ERL metabolites in 41 heart 
transplant patients and evaluated the effect of clinical and genetic factors on ERL pharmacokinetics. Non-targeted plasma 
metabolic profiling by ultra-performance liquid chromatography and high resolution quadrupole-time-of-flight mass spec-
trometry was used to identify novel metabolites associated with ERL dose requirement.
Results The determination of ERL metabolites revealed differences in metabolite patterns that were independent from clinical 
or genetic factors. Whereas higher ERL dose requirement was associated with co-administration of sodium-mycophenolic 
acid and the CYP3A5 expressor genotype, lower dose was required for patients receiving vitamin K antagonists. Global 
metabolic profiling revealed several novel metabolites associated with ERL dose requirement. One of them was identified 
as lysophosphatidylcholine (lysoPC) (16:0/0:0). Subsequent targeted analysis revealed that high levels of several lysoPCs 
were significantly associated with higher ERL dose requirement.
Conclusion For the first time, this study describes distinct ERL metabolite patterns in heart transplant patients and detected 
potentially new drug–drug interactions. The global metabolic profiling facilitated the discovery of novel metabolites associ-
ated with ERL dose requirement that might represent new clinically valuable biomarkers to guide ERL therapy.
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1 Introduction
Immunosuppressive therapy plays an essential role in the 
prevention of allograft rejection after heart transplanta-
tion (Azimzadeh et al. 2011). Since the use of calcineu-
rin inhibitors is limited by specific adverse effects like 
nephrotoxicity, newer drugs such as the mammalian tar-
get of rapamycin inhibitor everolimus (ERL) have been 
introduced to the immunosuppressive therapy (Eisen 
et al. 2003). Due to its renal-sparing mode of action and 
anti-proliferative effects slowing the progression of car-
diac allograft vasculopathy (CAV; the major long-term 
complication in cardiac transplant recipients), ERL has 
become an alternative immunosuppressant for these 
patients over recent years (Andreassen et al. 2014; Rai-
chlin and Kushwaha 2008). Nevertheless, administration 
of ERL is complicated by unpredictable inter- and intra-
individual variability in dose requirement and therapy 
response (Kovarik et al. 2003). To gain insight into the 
variability in ERL dose response, pharmacogenetic studies 
of genes encoding for proteins involved in the metabolism 
and transport of ERL have been conducted (Lemaitre et al. 
2012; Moes et al. 2014; Schoeppler et al. 2014). Similarly 
to calcineurin inhibitors, ERL is metabolized by enzymes 
of the cytochrome P450 (CYP) 3A family, CYP3A4 and 
CYP3A5, and to a lower extent by CYP2C8, resulting in 
mainly hydroxylated and demethylated metabolites (Fig. 1) 
(Kirchner et al. 2004). Although the loss-of-function vari-
ant CYP3A5*3 was reported to be associated with reduced 
ERL dose requirement (Lesche et al. 2015), the majority 
of the individual variability in ERL dose response remains 
unexplained (Chapman and Perry 2004).
Metabolomics, the newest of the emerging “omics” fields, 
studies the entire repertoire of small molecules present in 
biological samples (Patti et al. 2012). Due to recent techni-
cal advances, especially in mass spectrometry (MS), it is 
currently possible to rapidly measure thousands of metabo-
lites in small sample volumes (e.g. blood plasma) (Fang and 
Gonzalez 2014). Therefore, metabolic profiles can serve as 
direct signatures of biochemical activity of an organism, and 
thus, provide a more direct description of drug response phe-
notypes than data obtained with other “omics” approaches 
(Ramautar et al. 2013). Metabolic profiles reflect the com-
bined effect of genetic, environmental, and physiological 
factors on the individual drug response (Everett 2016). 
Indeed, it has been successfully shown in the pioneering 
pharmacometabolomic studies that good and poor therapy 
responders can be distinguished by screening plasma metab-
olites (Kaddurah-Daouk et al. 2015; Ji et al. 2011).
We applied a comprehensive pharmacometabolomic pro-
filing technique to address the variability in ERL metabo-
lism and therapy response in cardiac transplant patients. 
We first performed a targeted quantification of major ERL 
metabolites in combination with genetic analyses to identify 
clinical and genetic factors affecting ERL pharmacokinetics 
and dose requirement. Then, we applied global metabolic 
profiling to elucidate mechanisms underlying the substan-
tial inter-individual variability in ERL dose response. This 
study approach may thus provide a new promising strategy 
to identify factors predictive of individual variability in ERL 
dose response.
2  Methods
2.1  Patient population
All patients had received ERL-based maintenance immu-
nosuppressive therapy for at least two months at the time of 
study recruitment. The targeted ERL C0 level was 3–10 ng/
mL depending on concomitant immunosuppressive therapy. 
Lithium heparin and EDTA blood samples (S-monovette; 
Sarstedt, Nümbrecht, Germany) for metabolic profiling were 
collected in fasting state simultaneously with samples for 
routine laboratory analyses (i.e., ERL therapeutic drug mon-
itoring). Clinical data, including patient characteristics, ERL 
daily dose, ERL C0 levels, and information about additional 
immunosuppressive and concomitant drug therapy were 
retrieved from patient charts. Patients with acute infections, 
malignancies, or untreated metabolic diseases (i.e., new-
onset diabetes mellitus, thyroid disease, gout) were excluded 
from the study. Renal function was assessed by an estimate 















Fig. 1  ERL metabolism in the human liver and gut wall. Enzymes: 
cytochrome P450 3A5 (CYP3A5), cytochrome P450 3A4 (CYP3A4), 
cytochrome P450 2C8 (CYP2C8). Metabolites: hydroxypiperidine 
metabolites I & II (OH-piper’-I, OH-piper’-II); 24-hydroxy (24-OH), 
25-hydroxy (25-OH) and 46-hydroxy (46-OH) ERL; 16-O-desmethyl 
(16-O-DM) and 39-O-desmethyl (39-O-DM) ERL
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Chronic Kidney Disease Epidemiology Collaboration equa-
tion (Levey et al. 2009).
2.2  Quantification of ERL and its metabolites 
in plasma
EDTA whole blood samples were stored in 1.5 mL aliquots 
in CryoPure tubes (Sarstedt, Nümbrecht, Germany) at 
− 80 °C until shipment for analysis. Samples were shipped 
on dry ice to the iC42 Clinical Research and Development 
Facility at the University of Colorado Denver for quantifica-
tion of ERL and its major metabolites. Sample preparation 
and measurement were performed as previously described 
(Schniedewind et al. 2015; Strom et al. 2007b). Using a 
validated liquid chromatography coupled tandem mass 
spectrometry (LC-MS/MS)-based method on an Applied 
Biosystems/Sciex API4000 triple quadrupole MS (Applied 
Biosystems, Foster City, CA, USA), ERL and the follow-
ing metabolites were quantified: 46-hydroxy (46-OH) ERL, 
25-OH ERL, 24-OH ERL, 16-O-desmethyl (16-O-DM) 
ERL, hydroxypiperidine-I (OH-piper’-I) ERL, and 39-O-
DM ERL. The Analyst software v.1.6.2 (Sciex) was used to 
control the LC and MS components and process the data. 
The structures of the ERL metabolites were confirmed as 
previously described (Strom et al. 2007a; Boernsen et al. 
2007).
2.3  Metabolic profiling
2.3.1  Global metabolic profiling
Lithium heparin blood samples were centrifuged for 15 min 
at 2000×g and 4 °C and the separated plasma was stored in 
CapLock Microtubes (Treff AG, Degersheim, Switzerland) 
at − 140 °C until final sample preparation and analysis in a 
randomized order on a high-resolution quadrupole-time-of-
flight (qTOF-MS; Synapt G2-S HDMS, Waters, Milford, 
MA, USA) coupled to an ultra-performance liquid chro-
matography (UPLC) Acquity system (Waters). The sam-
ples were introduced by electrospray ionization operating 
in either negative ion (ESI−) or positive ion (ESI+) mode. 
The instrument was controlled via MassLynx v.4.1 (Waters). 
Raw data detection, run alignment, peak picking, and ion 
deconvolution were performed using Progenesis QI (Non-
linear Dynamics, Newcastle upon Tyne, UK). Additional 
information on the methods can be found in the Supplemen-
tary Material.
2.3.2  Targeted profiling of glycerophospholipids
Glycerophospholipids were quantified in heparin plasma 
samples stored at -140 °C by using the flow-injection analy-
sis based MS/MS assay  AbsoluteIDQ® p180 (Biocrates Life 
Sciences AG, Innsbruck, Austria). Metabolites were quanti-
fied using a Xevo TQ-S instrument (Waters). MetIDQ® soft-
ware (Biocrates Life Sciences AG) was used to manage plate 
set-up, peak integration as well as concentration calculation. 
Additional information is provided in the Supplementary 
Material.
2.4  Genetic analysis
Genomic DNA was isolated from EDTA blood samples 
(4  mL, stored at − 20  °C) using QIAamp DNA Blood 
Midi Kit (Qiagen AG, Basel, Switzerland). The variant 
CYP3A5*3 was genotyped using a  TaqMan® SNP Genotyp-
ing Assay (Assay ID C_26201809_30; Thermo Fisher Scien-
tific, Waltham, MA, USA) as previously described (Lesche 
et al. 2015). Genotype frequencies were tested for devia-
tions from Hardy–Weinberg equilibrium using exact tests 
implemented in the software Arlequin v.3.5.1.3 (Excoffier 
and Lischer 2010).
2.5  Statistical analyses
ERL and the corresponding metabolite concentrations were 
used to calculate metabolite/ERL concentration ratios. The 
dose-adjusted ERL C0 levels (i.e., ERL C0 level divided by 
the daily ERL dose per kg) were calculated using ERL C0 
and the daily dose at the day of sampling retrieved from 
the patient chart. The dose-adjusted ERL C0 level and the 
metabolite/ERL concentration ratios were normalized by 
logarithmic transformation for further analysis. Normal 
distribution of continuous clinical data was assessed by 
Kolmogorov–Smirnov test and data were presented as mean 
(± SD) or as median (min–max) where appropriate.
Associations of demographic and clinical factors (i.e., 
age, sex, time on ERL therapy, time after transplantation, 
lipoprotein levels, total cholesterol, triglyceride levels, and 
eGFR) and the genetic variant CYP3A5*3 with the dose-
adjusted ERL C0 and the concentration ratios were evaluated 
using analysis of variance (ANOVA) and Student’s t test for 
group-wise comparisons and linear regression and Pearson’s 
correlation for continuous variables. The influence of poten-
tially interacting co-medication (Furger and Suter 2009; 
Wessler et al. 2013) on the normalized dose-adjusted ERL 
C0 levels and daily ERL doses was assessed using Student’s 
t test and Mann–Whitney U test, respectively. Multiple linear 
regression modelling was used to identify clinical factors 
independently associated (P ≤ 0.05) with the dose-adjusted 
ERL C0 and used as covariates in non-targeted metabolite 
data analyses. Described statistical analyses were performed 
using IBM SPSS v.21.0 (IBM Corp., Armonk, NY).
Raw abundance data from non-targeted metabolic profil-
ing were normalized using a global normalization method 
over all measured compounds as implemented in Progenesis 
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QI (Nonlinear Dynamics). Obtained metabolic features were 
filtered according to peak width, charge, coefficient of varia-
tion in quality control (QC) samples, retention time, interfer-
ing co-medication, and interferences from the blood collec-
tion tubes as described in detail in Supplementary Material. 
Surveillance of system measurement stability was performed 
by visually checking for outliers in the QC samples in prin-
cipal component analysis (PCA) with Pareto scaled data as 
implemented in SIMCA v.14.0 (MKS Data Analytics Solu-
tions, Umeå, Sweden; Supplementary Fig. 1). For statisti-
cal evaluation of the metabolite data, the R software v.3.2 
(http://www.r-project.org) was used. The normalized dose-
adjusted ERL C0 level was set as a dependent variable, while 
metabolite peak data (i.e., normalized abundance) were set 
as predictor variables. For subsequent exhaustive model-
ling, a set of 50 best predictive variables was selected by 
car-scoring (i.e., computing correlation coefficients between 
the dependent and the Mahalanobis-decorrelated predictor 
variables) to limit the size of the model space (Kessey et al. 
2015; Burnham and Anderson 2002). Modelling was per-
formed using a standard glm function in R and exhaustive 
search for the best subsets of variables was performed using 
the package ‘leaps’ (Hernandez-Ruedas et al. 2014). The 
models were subsequently ranked according to Akaike’s 
Information Criterion (AIC) and the best model was chosen. 
Metabolic features remaining in the final model were revised 
for peak symmetry, all-over peak abundance and background 
noise, and peak distribution in all samples (i.e., clear peak in 
at least three patient samples) with Progenesis QI (Nonlinear 
Dynamics). Univariate linear regressions as well as linear 
regressions adjusted for clinical and genetic variables for 
each metabolic feature were calculated using SPSS. Puta-
tive metabolic features were annotated using the Human 
Metabolome Data Base (HMDB) (Wishart et al. 2013), 
LIPID MAPS (Fahy et al. 2007), KEGG (http://www.kegg.
jp/kegg/), Metlin (Smith et al. 2005), and MetFrag (Wolf 
et al. 2010), assuming a Δ m/z ≤ 10 ppm. Levels of metabo-
lite identification were defined as described in Sumner et al. 
(2007).
3  Results
The study cohort consisted of 41 cardiac transplant patients 
recruited at the University Hospital Bern. A subset of the 
patients (23/41; 56%) was also included in a previous study 
on ERL pharmacogenomics (Lesche et  al. 2015). The 
median age of the patients was 56 years and the major-
ity were males (29/41; 71%) and of Caucasian ethnicity 
(98%). On average, patients had been treated with ERL-
based maintenance therapy for 4.2 years at the time of study 
recruitment (Table 1). Four patients (10%) were treated 
with additional low-dose tacrolimus and 37 (90%) patients 
with mycophenolic acid (MPA) derivatives, which was the 
prodrug mycophenolate mofetil (MMF;  Cellcept®) for 21 
patients and the enteric-coated active sodium mycophe-
nolic acid (Na-MPA,  Myfortic®) for 16 patients. Twenty-
eight patients (68%) received additional immunosuppres-
sion with prednisone [median daily dose 4.4 (2.5–15.0) mg]. 
The co-administration of other drugs potentially interact-
ing with ERL pharmacokinetics is shown in Table 2. Eight 
patients with insulin-dependent diabetes mellitus received 
parenteral short- and long-acting insulin analogues. The fre-
quency of the genetic variant CYP3A5*3 was 88% and the 
observed genotype frequencies showed no deviation from 
Hardy–Weinberg equilibrium (P = 0.08).
3.1  Clinical and genetic factors associated with ERL 
pharmacokinetics
The dose-adjusted ERL trough (C0) levels showed over ten-
fold variability in our patient cohort with a median of 169.7 
(52.7–619.2) ng/mL per mg/kg/day. It was used as a quanti-
tative surrogate marker for ERL dose response in subsequent 
analyses. Four out of the six measured ERL metabolites 
were observed (Fig. 2). The main metabolites 46-hydroxy 
(46-OH) ERL and 24-hydroxy (24-OH) ERL accounted 
together for 71% of all ERL metabolites in whole blood. 
Although 46-OH ERL showed predominantly the highest 
abundance, 24-OH ERL was the main metabolite observed 
in six patients (Fig. 2).
The co-administration of Na-MPA was associated with 
lower dose-adjusted ERL C0 levels compared to treatment 
Table 1  Characteristics of the study cohort
Continuous data are presented as mean (± SD) or as median (min–
max) where appropriate
BMI body mass index, C0 trough level, ERL everolimus, eGFR esti-
mated glomerular filtration rate, LDL low-density lipoprotein
a n = 35
b n = 39
Variable n = 41
Time on ERL (years) 4.2 (± 2.8)
Time from transplantation (years) 6.1 (0.3–21.4)
Age (years) 56.3 (20.0–79.0)
BMI (kg/m2) 25.0 (± 4.5)
eGFR (mL/min/1.73 m2) 59.8 (22.6–148.7)
LDL (mmol/L) 3.0 (± 1.0)a
Total cholesterol (mmol/L) 5.4 (± 1.3)b
Triglycerides (mmol/L) 1.9 (0.8–10.3)b
ERL C0 (ng/mL) 6.4 (4.1–13.8)
ERL daily dose (mg) 2.5 (0.8–7.3)
ERL daily dose/weight (mg/kg) 0.04 (0.01–0.10)
Dose-adjusted ERL C0 (ng/mL per mg/kg/day) 169.7 (52.7–619.2)
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with the MMF (P = 0.013; Fig. 3a). This difference was 
translated to a higher daily ERL dose needed by patients 
treated with Na-MPA to reach their targeted C0 level 
(P = 0.008; Fig. 3b). Co-administration of vitamin K antago-
nists (i.e., phenprocoumon, or acenocoumarol) was associ-
ated with higher dose-adjusted ERL C0 levels compared to 
patients without this treatment, although the effect did not 
reach statistical significance (P = 0.135). CYP3A5 expres-
sors (i.e., patients with CYP3A5*1/*3 and CYP3A5*1/*1 
genotypes) showed slightly lower dose-adjusted ERL C0 
levels (P = 0.074) and received slightly higher ERL daily 
doses (P = 0.059) compared to CYP3A5 non-expressors (i.e., 
CYP3A5*3/*3 genotype; Fig. 3c, d). Additionally, an associ-
ation of lower dose-adjusted ERL C0 levels, indicative of an 
increased ERL dose requirement, with elevated low-density 
lipoprotein (LDL) levels was observed  (rPEARSON = − 0.348; 
P = 0.041). None of the factors associated with the dose-
adjusted ERL C0 level showed an effect on ERL metabo-
lite formation or the metabolite/ERL concentration ratios 
(data not shown). Higher 46-OH/ERL ratios were, however, 
observed in older patients  (rPEARSON = 0.360; P = 0.021).
The CYP3A5*3 genotype and co-medication with Na-
MPA and vitamin K antagonists were included as covari-
ates in the regression models of non-targeted metabolite 
data, since these variables were independently associated 
with the dose-adjusted ERL C0 level in a multivariate regres-
sion model (R2 = 0.345; P = 0.001). None of the other demo-
graphic or clinical factors showed an association with the 
dose-adjusted ERL C0 levels or metabolite/ERL concentra-
tion ratios.
3.2  Global metabolic profiling
Non-targeted metabolic profiling revealed a total of 1634 and 
718 ion features using positive and negative modes of ioni-
zation, respectively (Supplementary Table 1). All ion fea-
tures were subjected to statistical analysis as predictor vari-
ables. Because ERL (calculated exact mass 957.5814 Da) 
and associated [M + H]+, [M + Na]+, and [M + K]+ adducts 
were not detected using our LC-MS method when injecting 
analytical standards (data not shown), it was unlikely that 
related ions were included in the data set.
Including ion features identified in positive ionization 
mode, the model with the best fit obtained with exhaus-
tive linear regression modelling contained eight ions, from 
Table 2  Medication potentially 
interacting with ERL 
pharmacokinetics
INH-3A, moderate CYP3A4/5 inhibitor; INH-2C8, moderate CYP2C8 inhibitor; INH-PGP ,inhibitor of 
P-glycoprotein; SUB-3A, substrate of CYP3A4/5; SUB-2C8, substrate of CYP2C8; SUB-PGP, substrate of 
P-glycoprotein
a All other patients received fluvastatin, pravastatin or rosuvastatin which are not described to interact with 
CYP3A4/5, CYP2C8 or P-glycoprotein
Therapeutic Class Drug(s) Interaction n = 41
Immunosuppression Tacrolimus SUB-3A/SUB-PGP 4 (9.8%)
Antibiotics Trimethoprim SUB-2C8/INH-2C8 33 (80.5%)
Anticoagulant Phenprocoumon, acenocoumarol SUB-3A 8 (19.5%)
Clopidogrel SUB-PGP 6 (14.6%)
Ca2+-channel blocker Diltiazem INH-3A, INH-PGP 4 (9.8%)
Amlodipine SUB-3A 5 (12.2%)
H1-antagonist Es- and omeprazole SUB-3A/INH-3A 19 (46.3%)
Pantoprazole SUB-3A 9 (22.0%)
Lipid-lowering agent Ezetimibe SUB-PGP 16 (39.0%)
Atorvastatin,  simvastatina SUB-3A 6 (14.6%)
Fig. 2  Individual concentration profiles of ERL metabolites in whole 
blood samples of 41 cardiac transplant patients. Six patients (dashed 
line, open circles) showed higher 24-OH ERL concentrations com-
pared to 46-OH ERL, with lines connecting the metabolite data 
points of one individual. Metabolites: 46-hydroxy everolimus (46-OH 
ERL), 24-hydroxy everolimus (24-OH ERL), 25-hydroxy everolimus 
(25-OH ERL), 16-O-desmethyl everolimus (16-O-DM ERL)
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which six showed an acceptable peak shape and intensity 
in subsequent visual inspection (Supplementary Material, 
Table 3). Four ions showed associations with dose-adjusted 
ERL C0 levels independent of clinical and genetic factors. 
A linear regression model including these four features and 
the covariates accounted for 71% of the variability in the 
dose-adjusted ERL C0 levels (R2 = 0.714; P < 0.001). The 
ion with a peak at 3.54 min (136.0744 m/z) was the main 
contributor to this variability (partial R2 = 0.179), with high 
normalized peak abundance associated with increased dose-
adjusted ERL C0 levels (Fig. 4a). Although the feature could 
be identified as a compound with the sum formula  C8H9NO, 
a more precise identification was not possible due to missing 
recording of  MSE fragmentation data (MSI identification 
level 3). The other independently associated features could 
not be annotated by database search taking  MSE data into 
account (Supplementary Fig. 3). The ion feature detected 
at 7.01 min (415.1706 m/z) was identified as the calcium 
channel blocker diltiazem based on a database match and 
confirmation by  MSE fragmentation data (HMDB14487; 
MSI identification level 2). In this cohort, four patients were 
reported to be treated with diltiazem (Table 2), and from 
these patients, three showed high abundance peaks of this 
compound associated with increased dose-adjusted ERL C0 
levels. The compound was not detected in any other patient.
Similarly, for negative ionization mode, the model with 
the best fit obtained with exhaustive linear regression mod-
elling contained eight ion features, which all showed an 
acceptable peak shape and intensity (Table 3). Three fea-
tures were independently associated with the dose-adjusted 
ERL C0 level, when the analysis was adjusted for clinical 
and genetic co-variables. Normalized peak abundance of 
these three metabolites was positively correlated with the 
dose-adjusted ERL C0 level (Fig. 4e–g). A linear regression 
model including the three independently associated metabo-
lites and the co-variables explained 70% of the variability 
in the dose-adjusted ERL C0 levels (R2 = 0.703; P < 0.001). 
These metabolic features, however, could not be identified 
based on a database search (MSI identification level 4) using 
available  MSE data (Supplementary Fig. 4).
More than 85% of the inter-individual variability in dose-
adjusted ERL C0 levels could be explained with a multivari-
ate regression model (R2 = 0.855; P < 0.001) including all 
independently associated clinical and genetic factors and ion 
features measured in positive and negative ionization mode. 
The model also revealed a partial correlation between ion 
Fig. 3  Differences in the 
dose-adjusted ERL C0 levels 
and ERL dose in patients 
with co-administration of 
different MPA derivatives, 
i.e., mycophenolate mofetil 
(MMF, n = 21) and sodium 
mycophenolic acid (Na-MPA; 
n = 16) (a–b) and between 
CYP3A5 non-expressors 
(CYP3A5*3/*3) and CYP3A5 
expressors (CYP3A5*1/*3 and 
CYP3A5*1/*1) (c–d). The bot-
tom and top of the box represent 
the first and third quartiles, and 
the band inside is the median. 
Whiskers indicate minimum and 
maximum
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features indicating that they may belong to the same meta-
bolic pathway (Supplementary Fig. 2).
Interestingly, a metabolite detected at 10.91  min 
(480.3091 m/z), that was included in the original best-fit 
model, was tentatively identified as a lysophosphatidylcho-
line (16:0/0:0) [lysoPC (16:0/0:0); LMGP01050018] that 
showed a strong negative correlation with the dose-adjusted 
ERL C0 level (Table 3 and Fig. 4i). The identification of 
lysoPC (16:0/0:0) was confirmed by comparing its retention 
time and  MSE fragmentation data to those of an analyti-
cal standard using the same non-targeted method as above 
(MSI identification level 2, Supplementary Fig. 4i). Both 
showed a peak at 255.2331 m/z representing the [M–H]− ion 
of palmitic acid, the fatty acid residue present in lysoPC 
(16:0/0:0).
3.3  Targeted profiling of glycerophospholipids
To further explore the association of the identified lysoPC 
(16:0/0:0) as well as other lysoPC compounds with ERL 
dose requirement, glycerophospholipid profiling was per-
formed using the AbsoluteIDQ® p180 kit. In agreement with 
our previous results, the plasma concentration of lysoPC 
(16:0/0:0) showed a strong correlation with the normalized 
peak abundance of lysoPC (16:0/0:0) determined with the 
non-targeted approach  (rPEARSON = 0.886; P < 0.001). It also 
showed a similar negative correlation with the normalized 
dose-adjusted ERL C0 level (Fig. 4h). Additionally, two 
other lysoPC compounds, lysoPC (17:0/0:0) and lysoPC 
(18:0/0:0), showed a similar association with the dose-
adjusted ERL C0 level  (rPEARSON = − 0.536; P < 0.001 and 
 rPEARSON = − 0.455; P = 0.002, respectively).
4  Discussion
Although ERL is increasingly used in immunosuppressive 
therapy after cardiac transplantation, patients’ substantial 
variability in dose response remains a major hurdle for 
achieving successful therapy. The biological mechanisms 
underlying this variability are poorly understood, and bio-
markers predictive of individual ERL dose requirement for 
optimizing the therapy for each patient are still lacking. In 
this study, we combined quantification of drug metabolites 
and metabolic profiling to evaluate factors affecting ERL 
metabolism and to identify new metabolic biomarkers asso-
ciated with individual ERL dose response. By quantifying 
ERL and its metabolites in blood samples of 41 cardiac 
transplant patients, we observed the influence of co-medi-
cation and the genetic variant CYP3A5*3 on the daily ERL 
dose requirement. By using global plasma metabolic profil-
ing and a targeted analysis of glycerophospholipids, we were 
Table 3  Metabolic features 
detected with positive and 
negative ionization mode 
associated with dose-adjusted 
everolimus trough levels
a Calculated neutral mass based on detected adduct ions at the same retention time
b Adjusted for CYP3A5*3 genotype and therapy with Na-MPA and vitamin K antagonists
c C24H50NO7P, loss of a methyl group in negative mode
Bold font indicates P < 0.05






R2 P R2 P
Positive ionization mode
3.54 min 136.0744 m/z 0.270 < 0.001 0.467 0.005 Chemical formula:  C8H9NO
3.79 min 316.2110 m/z 0.190 0.004 0.438 0.014 None
4.23 min 247.0878  na 0.105 0.039 0.393 0.069 None
6.48 min 599.2454 m/z 0.102 0.042 0.405 0.045 None
6.63 min 232.1296  na 0.124 0.024 0.421 0.026 None
7.01 min 415.1706 m/z 0.041 0.205 0.380 0.112 Diltiazem
Negative ionization mode
5.65 min 229.0162 m/z 0.058 0.130 0.349 0.375 None
6.94 min 461.0052 na 0.082 0.070 0.385 0.094 None
7.82 min 525.2686 m/z 0.040 0.208 0.338 0.084 None
7.90 min 391.1824 m/z 0.114 0.031 0.409 0.039 None
8.31 min 427.2143 m/z 0.238 0.001 0.405 0.046 None
9.23 min 427.2145 m/z 0.142 0.015 0.378 0.120 None
9.27 min 550.2438 m/z 0.178 0.006 0.460 0.006 None
10.91 min 480.3091 m/z 0.197 0.004 0.400 0.054 Lysophosphatidylcholine 16:0/0:0c
 D. Lesche et al.
1 3
3 Page 8 of 11
able to identify lysoPCs as metabolites associated with ERL 
dose response.
The main metabolic pathway of ERL is mediated by 
CYP3A4 and CYP3A5 producing predominantly hydroxy-
lated ERL metabolites (Fig. 1). The 46-OH ERL was the 
major metabolite observed in the majority of our cardiac 
transplant patients. Interestingly, six patients (15%) showed 
an increased formation of the 24-OH ERL metabolite. The 
pharmacological and toxicological properties of ERL metab-
olites are currently unknown but they might be of clinical 
Fig. 4  Univariate regression of metabolic features independently 
associated with the dose-adjusted ERL C0 levels. Metabolic features 
were identified with positive (a–d) and negative (e–g) ionization 
mode in non-targeted metabolic profiling. Lysophosphatidylcholine 
(16:0/0:0) identified with the targeted AbsoluteIDQ p180 kit (h) and 
the non-targeted method in negative ionization mode at 10.91  min 
and 480.3091 m/z (i)
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relevance, especially regarding adverse drug effects. Strom 
et al. hypothesized that CYP3A5 genotype may contribute 
to differences in the formation of ERL metabolites (Strom 
et al. 2007b). Although we showed that the CYP3A5*3 vari-
ant might have a minor effect on ERL dose requirement, it 
was not associated with differences in ERL metabolite pat-
terns in our patient cohort. These differences were also not 
explained by the patients’ age, although an association of 
age with 46-OH ERL/ERL concentration ratio was observed, 
most likely reflecting lower ERL C0 levels in elderly patients 
 (rPEARSON = − 0.317; P = 0.043).
In this study, we report for the first time differences in the 
ERL dose requirement between cardiac transplant patients 
receiving the two different MPA derivatives, Na-MPA and 
MMF. Patients receiving Na-MPA therapy required signif-
icantly higher ERL doses to achieve their targeted blood 
levels compared to patients receiving MMF or no MPA 
derivative at all. ERL and MPA derivatives are frequently 
used in combination for immunosuppressive therapy after 
heart transplantation but interaction between the drugs has 
not been described earlier (Schweiger et al. 2012; Hollis 
et al. 2015). In our patient cohort, Na-MPA was usually pre-
scribed for patients suffering from severe gastrointestinal 
adverse effects under previous MMF therapy (Jasiak and 
Park 2016), while ERL therapy remained unchanged under 
this condition. Although co-administration of Na-MPA ther-
apy changed ERL dose requirement, it had no influence on 
the ERL metabolite patterns, which might suggest an inter-
action with ERL absorption. Further investigations are thus 
needed regarding the pharmacological background of this 
interaction and its clinical relevance. Similarly, the observed 
association between anticoagulation therapy with phenpro-
coumon or acenocoumarol and decreased ERL dose require-
ment needs further exploration. These drugs are reported to 
be substrates of CYP3A4 and CYP3A5 enzymes and exhibit 
extensive plasma protein binding (Ufer et al. 2004; Otagiri 
et al. 1980). Interaction with ERL might be caused by com-
petitive metabolism or protein binding in plasma but has not 
been described earlier.
Furthermore, we were able to detect diltiazem with the 
non-targeted metabolic profiling in the plasma of three out 
of four patients recorded to receive this drug. The ERL 
dose requirement of these patients corresponded with the 
diltiazem abundance, i.e., a lower dose requirement was 
associated with higher diltiazem levels. Nevertheless, 
the dose-adjusted ERL C0 levels in these patients were 
not significantly different from patients without reported 
diltiazem therapy in a group-wise comparison. In contrast 
to MPA derivatives and anticoagulants, diltiazem is known 
to interact with ERL pharmacokinetics by moderate inhi-
bition of CYP3A4- and CYP3A5-mediated metabolism 
and has been reported to lead to significantly increased 
dose-adjusted ERL C0 levels in lung transplant patients 
(Schoeppler et  al. 2014). Nevertheless, our study was 
limited to detect even large interaction effects in pairwise 
comparisons due to the small sample size and only four 
patients with diltiazem co-medication, thus diltiazem was 
only found to contribute to the regression model of meta-
bolic features obtained with positive ionization mode in 
global metabolic profiling.
The putative identification of the lysoPC (16:0/0:0) by 
our global metabolic profiling was supported by confir-
mation with an analytical standard and observation of a 
similar negative correlation of lysoPC (16:0/0:0) plasma 
concentration with dose-adjusted ERL C0 level using tar-
geted profiling of glycerophospholipids. Two additional 
lysoPCs, namely lysoPC (17:0/0:0) and lysoPC (18:0/0:0), 
were identified to be similarly associated with ERL dose 
requirement through targeted glycerophospholipid analy-
sis. While lysoPC (17:0/0:0) is usually observed only in 
low levels in human tissue, lysoPC (16:0/0:0) and lysoPC 
(18:0/0:0) are the most abundant lysoPCs in human plasma 
and have been reported to differ between lipoproteins 
(Serna et al. 2015).
The negative correlation observed between lysoPC con-
centrations and the dose-adjusted ERL C0 level indicates an 
association of lower plasma lysoPC levels with a reduced 
ERL dose requirement. Circulating lysoPCs are generated by 
lecithin-cholesterol acyltransferase, which is secreted from 
the liver, and transfers fatty acids from phosphatidylcholines 
(PC) to cholesterol. Alternatively, lysoPCs can be produced 
by lipoprotein-associated phospholipase  A2 (Lp-PLA2) by 
hydrolysis of surface PC of lipoproteins (Schmitz and Rueb-
saamen 2010; Matsumoto et al. 2007; Tellis and Tselepis 
2009). Lp-PLA2 activity is associated with LDL levels and 
has been proposed to be a biomarker for atherosclerotic pro-
cesses and vascular inflammation, such as CAV, in combina-
tion with high levels of lysoPCs (Lavi et al. 2007; Schmitz 
and Ruebsaamen 2010). We observed that patients requiring 
lower ERL doses to achieve targeted ERL C0 levels also 
showed lower lysoPC levels independent from lipid-low-
ering therapy. In contrast, an increased ERL dose require-
ment was associated with higher lysoPC levels potentially 
reflecting inflammatory processes triggered by inadequate 
immunosuppression. Thus, patients with a poor response to 
ERL might be at a higher risk of developing long-term CAV. 
These patients might not equally benefit from the generally 
positive effects of ERL on vascular remodeling after car-
diac transplantation (Eisen et al. 2003; Hiemann et al. 2011). 
Rosing et al. (2013) described increased Lp-PLA2 activity as 
a biomarker for oxidative stress potentially involved in the 
development of CAV in heart transplant recipients on ERL-
based therapy. However, it remains to be clarified whether 
patients with poor ERL dose response equally benefit from 
anti-proliferative ERL effects compared to good responders.
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4.1  Concluding remarks
For the first time in cardiac transplant recipients, differ-
ent ERL metabolite patterns were described. These pat-
terns were not influenced by CYP3A5*3 genotype or co-
medication. The combined quantification of ERL and its 
metabolites and global metabolic profiling allowed us to 
detect potentially new drug–drug interactions and novel 
metabolites associated with ERL dose requirement. Espe-
cially the role of lysoPCs as biomarkers for CAV-related 
inflammatory processes, possibly triggered by inadequate 
immunosuppression, requires further investigation in order 
to understand their role in altered ERL dose requirement.
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